Argireline (Acetyl Hexapeptide-8) Cosmetic ingredient

Skin

Argireline (Acetyl Hexapeptide-8)

A peptide used in cosmetic skin creams

Cosmetic ingredient · not sold by RiptideRx
Why it’s a cosmetic
Stylised model of the real sequence

Overview.

Argireline is a cosmetic ingredient, not an FDA-approved drug. It is the trade name for a synthetic hexapeptide whose current INCI (International Nomenclature of Cosmetic Ingredients) name is Acetyl Hexapeptide-8; older literature and some regulatory databases (e.g., WHO Drug Dictionary) still list it as Acetyl Hexapeptide-3, and both names refer to the identical molecule. It is used mainly in topical creams and serums, marketed as a needle-free alternative to botulinum toxin for expression lines. In the US its legal status depends on the claims made: FDA treats claims to remove wrinkles, boost collagen or act like Botox as drug claims.

Also known as Acetyl Hexapeptide-3 · Acetyl Hexapeptide-8 · Argireline NP · HEX-3

The molecule, decoded.

Sequence

Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2

Length
6 residues
Molecular weight
889 g/mol
Formula
C34H60N14O12S
CAS number
616204-22-9
Half-life
Not established
Routes studied
topical (creams/serums; the only route studied in humans; injection is unstudied, though research vials are sold and injected use has been reported)
Modifications
N-terminal acetylation; C-terminal amidation

How it works.

The peptide is modeled on the N-terminal domain of SNAP-25, a protein required for SNARE-complex assembly at the presynaptic membrane. By competitively interfering with SNARE complex formation, it is proposed to reduce vesicle docking and acetylcholine release at the neuromuscular junction, weakening muscle-contraction-driven expression wrinkles -- the same general target as botulinum toxin but via a much weaker, non-injectable, topical mechanism with uncertain skin/neuromuscular-junction penetration.

Evidence · Early or small human studies

What the research shows

human RCT2013

In a randomized, placebo-controlled trial of 60 Chinese subjects applying topical argireline or placebo to peri-orbital wrinkles for 4 weeks, subjective anti-wrinkle efficacy was 48.9% in the argireline group versus 0% for placebo, and objective silicone-replica roughness measurements decreased significantly (p<0.01) only in the argireline group.

60 adult subjects, China, peri-orbital wrinkles

Source
narrative review2025

A 2025 cosmeceutical review noted that acetyl hexapeptide-8's hydrophilic, relatively large structure limits penetration through the stratum corneum, leaving its ability to reach neuromuscular junctions topically uncertain and its exact mechanism incompletely validated in vivo; it said preclinical and clinical studies indicate it may reduce wrinkle depth, improve skin elasticity and enhance hydration.

review of preclinical and clinical cosmeceutical literature

Source
in vitro2025

In a sensory-neuron-integrated human skin spheroid model plus ex vivo human skin, acetyl hexapeptide-3 (the same molecule) crossed the stratum corneum and accumulated in deeper skin layers ex vivo, was taken up by spheroid cells (concentrating around sensory neurons), suppressed acetylcholine release, upregulated the antioxidant enzyme SOD2 and stimulated type I collagen synthesis; in aged human skin samples it significantly increased collagen. (A correction to this paper was published in September 2026.)

human skin spheroid model and ex vivo human skin samples

Source

What to know first.

Based on: small trials of topical products and lab studies.

Reported side effects

  • Injected use (not an approved or studied route): a 2021 case report describes Mycobacterium abscessus infection, with redness, nodules and abscesses at forehead and temple injection sites one week after argireline injections, which needed 5 months of antibiotics

Cautions

  • As a cosmetic ingredient it is not subject to the efficacy/safety review a drug would receive; claims of botulinum-toxin-like efficacy are not clinically equivalent to actual botulinum toxin injection
  • Skin-penetration data are mixed -- reviews note uncertainty over whether topically applied peptide reaches the neuromuscular junction in meaningful concentrations

Checked 2026-09

Where it stands.

Cosmetic ingredient · not sold by RiptideRx. Argireline (Acetyl Hexapeptide-8) is used as an ingredient in cosmetic skincare. It is not approved as a drug for injection or any medical use, and RiptideRx does not sell it.
FDA
Not an FDA-approved drug, and not FDA-reviewed. Whether a product containing it is a cosmetic or a drug depends on its intended use. FDA treats products intended to affect the structure or function of the skin, for example to remove wrinkles, boost collagen or relax muscles, as drugs, and it has cited claims such as 'Hexapeptide 3… reduces wrinkles' and 'Natural Botox Alternative' as unapproved-drug claims (warning letter to Star Health & Beauty, 2017). Sold with appearance-only claims, it is a cosmetic ingredient: cosmetics need no FDA premarket approval but must be safe and properly labeled. It was not reviewed at the July 2026 PCAC.
Compounding
It has no route to 503A compounding: it is not a component of an FDA-approved drug, is not on the 503A Bulks List or in any 503A category, and has no applicable USP/NF monograph. For 503B outsourcing facilities, FDA's category list places 'Acetyl Hexapeptide-3' in Category 3, 'Bulk Drug Substances Nominated Without Adequate Support' (list updated 21 Mar 2025); only 503B Category 1 substances fall under FDA's interim policy. It is not on FDA's Category 2 safety-risk list (page current as of 22 Apr 2026) and was not reviewed at the July 2026 PCAC.
Sport (WADA)
Not named in the WADA 2026 Prohibited List or in the 2027 List published in September 2026. Topical cosmetic use has no known performance effect. However, it is not approved as a medicine, so WADA's catch-all S0 class ('any pharmacological substance ... with no current approval by any governmental regulatory health authority for human therapeutic use') could apply to non-cosmetic use such as injection.
Enforcement
  • FDA's 26 May 2017 warning letter to Star Health & Beauty LLC cited website claims including 'Hexapeptide 3… reduces wrinkles… Also has been shown to prevent aging of the skin' (Realyze Under Eye Seryum) and 'Natural Botox Alternative' (Royal Touch Anti-Wrinkle Serum) as evidence that its skin products were unapproved new drugs.
References (9)
  1. PubMed · PMID 23417317
  2. PubMed Central · PMC12193160
  3. PubMed · PMID 40410664
  4. U.S. FDA · certain bulk drug substances use compounding may present signifi
  5. World Anti-Doping Agency
  6. U.S. FDA · star health beauty llc 516206 05262017
  7. U.S. FDA · it cosmetic drug or both or it soap
  8. U.S. FDA · wrinkle treatments and other anti aging products
  9. U.S. FDA · download

More in Skin

Melanotan IINot availableMelanotan I / AfamelanotideFDA-approved · specialist care